The role of heparins and nano-heparins as therapeutic tool in breast cancer
- 24 October 2016
- journal article
- review article
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 34 (3) , 299-307
Abstract
Glycosaminoglycans are integral part of the dynamic extracellular matrix (ECM) network that control crucial biochemical and biomechanical signals required for tissue morphogenesis, differentiation, homeostasis and cancer development. Breast cancer cells communicate with stromal ones to modulate ECM mainly through release of soluble effectors during cancer progression. The intracellular cross-talk between cell surface receptors and estrogen receptors is important for the regulation of breast cancer cell properties and production of ECM molecules. In turn, reorganized ECM-cell surface interface modulates signaling cascades, which regulate almost all aspects of breast cell behavior. Heparan sulfate chains present on cell surface and matrix proteoglycans are involved in regulation of breast cancer functions since they are capable of binding numerous matrix molecules, growth factors and inflammatory mediators thus modulating their signaling. In addition to its anticoagulant activity, there is accumulating evidence highlighting various anticancer activities of heparin and nano-heparin derivatives in numerous types of cancer. Importantly, heparin derivatives significantly reduce breast cancer cell proliferation and metastasis in vitro and in vivo models as well as regulates the expression profile of major ECM macromolecules, providing strong evidence for therapeutic targeting. Nano-formulations of the glycosaminoglycan heparin are possibly novel tools for targeting tumor microenvironment. In this review, the role of heparan sulfate/heparin and its nano-formulations in breast cancer biology are presented and discussed in terms of future pharmacological targeting.Keywords
Funding Information
- eu (Ref. No. 645756.)
This publication has 67 references indexed in Scilit:
- Extracellular matrix structureAdvanced Drug Delivery Reviews, 2016
- Proteoglycan form and function: A comprehensive nomenclature of proteoglycansMatrix Biology, 2015
- Binding and inhibition of drug transport proteins by heparinCancer Biology & Therapy, 2013
- Perturbation of the heparin/heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3K/Akt and MAPK/ERK signallingThrombosis and Haemostasis, 2013
- Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplexBiomaterials, 2012
- NFAT promotes carcinoma invasive migration through glypican-6Biochemical Journal, 2011
- Polyproline‐type helical‐structured low‐molecular weight heparin (LMWH)‐taurocholate conjugate as a new angiogenesis inhibitorInternational Journal of Cancer, 2008
- Growth factor–induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cellsJournal of Cell Biology, 2005
- Serglycin Is Essential for Maturation of Mast Cell Secretory GranuleJournal of Biological Chemistry, 2004
- Glypican-3 expression is silenced in human breast cancerOncogene, 2001